Empowered Patient Podcast

Brad Margus, CEO, Cerevance talks about discovering and developing novel therapies for central nervous system diseases using the Cerevance powerful NETSseq target discovery platform and their large collection of human brain tissue samples.  Brad explains why the brain is such a challenging organ to study and their efforts to understand brain cell loss in such diseases as Parkinson's and Alzheimer's. #brain #CNSdisorders #Parkinsons #Alzheimers #NETSseq Cevevance.com Download the transcript here

Brad Robinson, CEO, Predictive Technology Group talks about the company's work focusing on women's health and why they decided to focus on this neglected field that has significant unmet medical needs.  Brad discusses the importance of genetics in informing a woman's course of care.  Brad also talks about the company's subsidiaries Predictive Analytics, Predictive Laboratories, and Predictive Biotech and how the synergy between these entities is instrumental in helping women and their clinicians address endometriosis and other reproductive health concerns. #womenshealth #endometriosis #infertility #fertility #genetics #pregnancy #preeclampsia PredTechGroup.com Download the transcript here

Ulf Jungnelius MD, CEO, Isofol Medical discusses the increasing incidence of colorectal cancer as a global issue and the current challenges in treating this devastating disease.  Dr. Jungnelius also talks about the company's drug candidate, arfolitixorin, currently being studied in a global Phase 3 clinical trial with the aim to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer. #colorectalcancer #CRC #ColonCancer #MetastaticColorectalCancer #chemotherapy #FirstLineTreatment Isofolmedical.com Download the transcript here

Purnanand Sarma, CEO, Immunome discusses why a lot of cancers still remain untreatable today and the company's new approach to fight cancer by tapping into the body's natural immune response against disease.  Sarma further talks about why Immunome chose to look at cancer through the lens of the B-cell in order to identify novel antibody-target pairs. #BCell #Antibody #ImmuneResponse #cancer Immunome.com Download the transcript here  

Filippo Petti, CEO, Celyad discusses how the company is broadening precision medicine by developing CAR-T immunotherapies to express a natural killer receptor that can recognize and target multiple ligands expressed in up to 80% of all cancers.  Filippo talks about the value to cancer patients of both personalized (autologous) and off the shelf (allogeneic) CAR-T therapies and CYAD-101, Celyad's allogeneic CAR-T therapy, that demonstrated for the first time ever, clinical effectiveness in solid tumors. @CelyadSA #CAR_T #NKCells #cancer #immunotherapy #CellTherapy #solidtumors #Tcell #CYAD101 #allogeneic $CYAD Celyad.com Download the transcript here

Nevan Elam, J.D. CEO and co-founder Rezolute, Inc. talks about their work developing therapeutics for congenital hyperinsulinism, a rare pediatric disease and for diabetic macular edema, a vision-related complication of diabetes.  With a background of working with technology businesses, Nevan reflects on lessons learned and differences in drivers of innovation in the computer and biotech worlds. @rezolutebio #RareDisease #PediatricDisease #DME #DiabeticMacularEdema #Diabetes #hyperinsulinism RezoluteBio.com Download the transcript here

Anat Cohen-Dayag PhD chief executive officer, Compugen discusses the current immune-oncology treatment landscape, with only 20-30% of patients responding to currently available treatments, and the missing link that she believes her company may have found to improve the success rate.  Anat talks about how Compugen's computational discovery platform works to discover new drug targets for treating solid tumors and how lead candidate COM701 has shown encouraging early stage results to date. #immuno-oncology  #cancer. #colorectalcancer Compugen Download the transcript here  

Ronnie Andrews, CEO, Oncocyte discusses the company's mission to answer critical questions along the cancer care continuum through the use of their molecular tests for diagnosis and treatment of early stage lung cancer.  Ronnie also talks about the changes in cancer care over the past 20 years and the potential these tests have to positively impact patients in the future. @oncocyteLBX #moleculardiagnostics  #lungcancer  #liquidbiopsy  #earlydetection Oncocyte.com Download the transcript here

Brad Younggren MD, Chief Medical Officer, 98point6 talks about what happens when a company fundamentally changes the way patients interact with doctors by providing 24/7 on-line access to medical professionals aided by the camera and attachments on mobile devices to further inform the diagnosis and treatment plan.  With enthusiastic support from traditional primary care doctors, this new model of on-demand care is showing effectiveness for addressing emergency as well as chronic conditions. @98point6inc 98point6.com Download the transcript here

Usama Malik, Chief Financial Officer and Chief Business Officer, Immunomedics discusses the challenges of developing effective medicines for people with triple negative breast cancer as well as Immunomedics' development of antibody-drug conjugates, directed therapies which have potential to provide new options for those with hard to treat cancers. @immunomedicsinc #breastcancer  #TNBC  #HER2  #TripleNegative  #bladdercancer  #urothelial Immunomedics.com Download the transcript here